Clean Science and Technology reported a consolidated Q2 revenue of Rs 299.39 crore, up from Rs 244.6 crore YoY. Profit remained steady at Rs 55.72 crore, though down sequentially. The company also signed an exclusive global manufacturing pact for HALS products with Switzerland-based Geneum Chem AG and addressed a Rs 7.37 crore GST liability.
Clean Science Q2 Results: Revenue Growth Meets Global Expansion
Revenue from operations reached Rs 299.39 crore for the quarter ended September 30, 2026.
Net profit for the same period stood at Rs 55.72 crore.
Reader Takeaway: Strong revenue growth shows operational scale, while the new Swiss HALS partnership offers a clear international growth path.
What just happened
Clean Science and Technology Limited released its unaudited financial results for the quarter and half-year ending September 30, 2026. While the company recorded year-on-year growth in both revenue and profit, net profit saw a sequential decline from Rs 73.35 crore in the June 2026 quarter. Simultaneously, the company announced a strategic long-term collaboration with Switzerland-based Geneum Chem AG for the exclusive global supply of Hindered Amine Light Stabilizers (HALS).
Why this matters
The HALS agreement is a significant strategic move for Clean Science, signaling a deeper entry into specialized high-performance chemicals. By securing exclusive off-take commitments and defined pricing structures, the firm aims to diversify its product mix and stabilize long-term international revenue. This offsets concerns regarding the recent GST inspection, which resulted in a Rs 7.37 crore liability that the company has already settled.
The backstory
The Maharashtra GST Department conducted search and inspection proceedings at the company's manufacturing and registered offices. The company addressed this by paying the identified liability of Rs 7.37 crore and additionally provisioned Rs 2.02 crore for related interest and tax adjustments within these financial results.
Risks to watch
Investors should monitor the integration of the HALS project and ensure that sequential profit dips do not become a trend in upcoming quarters. Regulatory updates regarding the GST proceedings, if any, remain a point of vigilance for shareholders.
What to track next
Watch for the scale-up timeline of the Geneum Chem AG partnership and how the company’s profit margins behave as the HALS business model begins to contribute to the bottom line.